Results 241 to 250 of about 67,431 (260)

Resistance to imatinib (Glivec): update on clinical mechanisms

Drug Resistance Updates, 2003
Ellen Weisberg, James D Griffin
exaly  

Imatinib

Reactions Weekly, 2014
openaire   +1 more source

Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

Journal of Clinical Pharmacology, 2004
Renaud Capdeville
exaly  

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

Cancer, 2009
Hagop Kantarjian, Saengsuree Jootar, Jerzy Holowiecki   +2 more
exaly  

Imatinib

Reactions Weekly, 2016
openaire   +2 more sources

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Nature Reviews Clinical Oncology, 2009
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge E Cortes   +2 more
exaly  

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells

Cancer Letters, 2008
Manlio Tolomeo, Stefania Grimaudo, Antonietta Di Cristina   +2 more
exaly  

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia, 2012
Richard A Larson, Andreas Hochhaus, Timothy P Hughes   +2 more
exaly  

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

Proceedings of the National Academy of Sciences of the United States of America, 2006
Junya Kuroda, Hamsa Puthalakath, Mark S Cragg   +2 more
exaly  

Imatinib

Reactions Weekly, 2006
openaire   +1 more source